Retrospective study results for IMMray™ PanCan-d conclude Immunovia needs to do further optimizations to meet the expected performance
Immunovia AB (publ) (“Immunovia”) finalized today a retrospective study performed as part of the preparation for the certification and accreditation of the company’s commercial version of their IMMrayTM PanCan-d assay for early detection of pancreatic cancer. Due to variations in different biobank blood sampling processes, Immunovia needs to do further optimizations to the test algorithms to meet the expected performance for its commercial version of the test. The further optimization work will delay the initiation of the sales of the IMMrayTM PanCan-d until later part of 2019 and in